Cited by 140

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The Human Papillomavirus E6 Oncoprotein Targets USP15 and TRIM25 To Suppress RIG-I-Mediated Innate Immune Signaling

Chiang, Cindy, Pauli, Eva-Katharina, Biryukov, Jennifer, Feister, Katharina F., Meng, Melissa, White, Elizabeth A., Münger, Karl, Howley, Peter M., Meyers, Craig, Gack, Michaela U.·2018·Journal of Virology

Abstract

Retinoic acid-inducible gene I (RIG-I) is a key pattern recognition receptor that senses viral RNA and interacts with the mitochondrial adaptor MAVS, triggering a signaling cascade that results in the production of type I interferons (IFNs). This signaling axis is initiated by K63-linked ubiquitination of RIG-I mediated by the E3 ubiquitin ligase TRIM25, which promotes the interaction of RIG-I with MAVS. USP15 was recently identified as an upstream regulator of TRIM25, stabilizing the enzyme through removal of degradative K48-linked polyubiquitin, ultimately promoting RIG-I-dependent cytokine responses. Here, we show that the E6 oncoprotein of human papillomavirus type 16 (HPV16) as well as of other HPV types form a complex with TRIM25 and USP15 in human cells. In the presence of E6, the K48-linked ubiquitination of TRIM25 was markedly increased, and in line with this, TRIM25 degradation was enhanced. Our results further showed that E6 inhibited the TRIM25-mediated K63-linked ubiquitination of RIG-I and its CARD-dependent interaction with MAVS. HPV16 E6, but not E7, suppressed the RIG-I-mediated induction of IFN-β, chemokines, and IFN-stimulated genes (ISGs). Finally, CRISPR-Cas9 gene targeting in human keratinocytes showed that the TRIM25-RIG-I-MAVS triad is important for eliciting an antiviral immune response to HPV16 infection. Our study thus identifies a novel immune escape mechanism that is conserved among different HPV strains and further indicates that the RIG-I signaling pathway plays an important role in the innate immune response to HPV infection. IMPORTANCE Persistent infection and tumorigenesis by HPVs are known to require viral manipulation of a variety of cellular processes, including those involved in innate immune responses. Here, we show that the HPV E6 oncoprotein antagonizes the activation of the cytoplasmic innate immune sensor RIG-I by targeting its upstream regulatory enzymes TRIM25 and USP15. We further show that the RIG-I signaling cascade is important for an antiviral innate immune response to HPV16 infection, providing evidence that RIG-I, whose role in sensing RNA virus infections has been well characterized, also plays a crucial role in the antiviral host response to small DNA viruses of the Papillomaviridae family.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.01737-17

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 67

  1. 10.1016/j.mib.2015.03.001 · DOI
  2. 10.1016/j.cell.2010.01.022 · DOI · Paper page
  3. 10.1126/science.1132505 · DOI · Paper page
  4. 10.1016/j.virol.2015.03.013 · DOI
  5. Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, Lin R, Hiscott J. 2006. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell Mol Biol (Noisy-le-Grand) 52:17–28.
  6. 10.1016/j.cell.2005.08.012 · DOI · Paper page
  7. 10.1016/j.molcel.2005.08.014 · DOI
  8. 10.1016/j.it.2016.10.008 · DOI
  9. 10.1073/pnas.0804947105 · DOI
  10. 10.1038/nature05732 · DOI
  11. 10.1016/j.immuni.2012.03.022 · DOI
  12. 10.1038/nature13140 · DOI
  13. 10.1016/j.celrep.2016.06.070 · DOI
  14. 10.1016/j.molcel.2010.12.029 · DOI · Paper page
  15. 10.1126/scisignal.2004577 · DOI
  16. 10.1128/JVI.00605-09 · DOI
  17. 10.1016/j.vaccine.2012.06.083 · DOI
  18. 10.1515/hsz-2017-0113 · DOI · Paper page
  19. 10.1016/j.coviro.2015.09.001 · DOI
  20. 10.1002/path.4496 · DOI
  21. 10.1038/nrc2886 · DOI
  22. 10.1002/j.1460-2075.1989.tb08570.x · DOI · Paper page
  23. 10.1128/jvi.63.10.4417-4421.1989 · DOI · Paper page
  24. 10.1016/0092-8674(93)90384-3 · DOI · Paper page
  25. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620–4624.
  26. 10.1128/JVI.00881-07 · DOI · Paper page
  27. 10.1128/mBio.01530-16 · DOI · Paper page
  28. 10.1089/jir.2009.0075 · DOI
  29. 10.1016/j.virusres.2016.11.004 · DOI
  30. 10.1016/j.virusres.2016.11.023 · DOI
  31. 10.4049/jimmunol.178.5.3186 · DOI
  32. 10.1126/science.aab3291 · DOI · Paper page
  33. 10.1371/journal.pone.0017848 · DOI
  34. 10.1038/nrmicro.2016.45 · DOI
  35. 10.1016/j.virol.2013.04.026 · DOI
  36. 10.1016/j.cub.2005.05.059 · DOI
  37. 10.1126/science.1323879 · DOI
  38. 10.1016/j.virol.2004.02.011 · DOI
  39. 10.1371/journal.ppat.1003384 · DOI
  40. 10.1038/nature00826 · DOI
  41. 10.1042/BSR20170805 · DOI
  42. 10.1038/onc.2015.21 · DOI
  43. 10.1038/srep19070 · DOI
  44. 10.1002/ijc.31027 · DOI
  45. 10.1371/journal.ppat.1004466 · DOI
  46. 10.1128/JVI.74.9.4174-4182.2000 · DOI
  47. 10.1074/jbc.275.10.6764 · DOI · Paper page
  48. Perea SE, Massimi P, Banks L. 2000. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int J Mol Med 5:661–666.
  49. 10.1128/JVI.05279-11 · DOI · Paper page
  50. 10.1101/gad.12.13.2061 · DOI · Paper page
  51. 10.1016/j.immuni.2013.05.007 · DOI
  52. 10.1016/j.it.2016.12.004 · DOI
  53. 10.1128/JVI.00748-16 · DOI
  54. 10.1038/ni.1779 · DOI
  55. 10.1016/j.cell.2009.06.015 · DOI
  56. 10.1099/vir.0.005389-0 · DOI
  57. 10.1016/j.chom.2016.10.011 · DOI
  58. 10.1038/s41590-017-0005-y · DOI
  59. 10.1128/JVI.01197-14 · DOI
  60. 10.1128/JVI.02172-12 · DOI · Paper page
  61. 10.1371/journal.ppat.1005701 · DOI
  62. 10.1128/JVI.00487-12 · DOI
  63. 10.1128/JVI.02241-09 · DOI
  64. 10.1007/978-1-4939-2013-6_24 · DOI
  65. 10.1128/JVI.00731-09 · DOI
  66. 10.1371/journal.pone.0022427 · DOI
  67. 10.1371/journal.pone.0016405 · DOI

Metadata

Authors
Chiang, C., Pauli, E.-K., Biryukov, J., Feister, K. F., Meng, M., White, E. A., Münger, K., Howley, P. M., Meyers, C., & Gack, M. U.
Affiliations
  • Department of Microbiology, The University of Chicago, Chicago, Illinois, USA
  • Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA
  • Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
  • Department of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  • Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA
Venue
Journal of Virology
Published
2018-03-15
Volume
92
Issue
6
ISSN
  • 0022-538X
  • 1098-5514
Cited by
140
References
6
Language
en
Funders
  • The Alexander & Margaret Stewart Trust Foundation
  • German Research Foundation (PA2090/1-1)
  • HHS | National Institutes of Health (CA197262, CA066980)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (AI087846)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review